Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs has cancelled 232,345 fully paid ordinary shares following the completion of an on-market share buy-back. The reduction in issued capital marginally increases the ownership percentage of remaining shareholders and reflects ongoing capital management by the company.
The cessation of these securities, effective 20 April 2026, was formally notified to the market in line with ASX requirements. While the transaction is small relative to typical market capitalisations, it signals continued use of buy-backs as a tool to optimise the company’s balance sheet and shareholder returns.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.20 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian-listed healthcare company operating in the medical diagnostics and pathology testing industry. The group provides laboratory and related clinical testing services, supporting doctors, hospitals, and healthcare providers across the country through its network and pathology operations.
Average Trading Volume: 854,184
Technical Sentiment Signal: Sell
Current Market Cap: A$392.7M
Learn more about ACL stock on TipRanks’ Stock Analysis page.